About Zinc finger protein 117
Zinc finger protein 117 (ZNF117) is a protein
from Homo sapiens identified by UniProt accession
Q03924, 483 residues long.
MolForge cross-references it against 0 known binders and
52 disease associations.
Target properties
| Protein name | Zinc finger protein 117 |
| UniProt accession | Q03924 |
| Gene | ZNF117 |
| Organism | Homo sapiens |
| Length | 483 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (52)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.49
- retinitis pigmentosa · score 0.07
- Leber congenital amaurosis · score 0.05
- neoplasm · score 0.05
- aniridia · score 0.05
- Aniridia-intellectual disability syndrome · score 0.04
- Familial ocular anterior segment mesenchymal dysgenesis · score 0.04
- congenital glaucoma · score 0.04
- retinitis pigmentosa 71 · score 0.04
- isolated optic nerve hypoplasia · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q03924-F1 | alphafold | PREDICTED | 76.01 | — |
Amino-acid sequence (483 residues)
MKRHEMVAKH LVMFYYFAQH LWPEQNIRDS FQKVTLRRYR KCGYENLQLR KGCKSVVECK QHKGDYSGLN QCLKTTLSKI FQCNKYVEVF HKISNSNRHK MRHTENKHFK CKECRKTFCM LSHLTQHKRI QTRVNFYKCE AYGRAFNWSS TLNKHKRIHT GEKPYKCKEC GKAFNQTSHL IRHKRIHTEE KPYKCEECGK AFNQSSTLTT HNIIHTGEIP YKCEKCVRAF NQASKLTEHK LIHTGEKRYE CEECGKAFNR SSKLTEHKYI HTGEKLYKCE ECGKAFNQSS TLTTHKRIHS GEKPYKCEEC GKAFKQFSNL TDHKKIHTGE KPYKCEECGK AFNQLSNLTR HKVIHTGEKP YKCGECGKAF NQSSALNTHK IIHTGENPHK CRESGKVFHL SSKLSTCKKI HTGEKLYKCE ECGKAFNRSS TLIGHKRIHT GEKPYKCEEC GKAFNQSSTL TTHKIIHTEE KQYKCDECGK AST
Explore Zinc finger protein 117 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets